Philips and March of Dimes Bring Maternal and Pregnancy Health Content to Philips Avent Pregnancy+ App
The new content will also emphasize the benefits of low dose aspirin, when clinically appropriate, as a preventive treatment for hypertensive disorders of pregnancy, including preeclampsia, aligning with March of Dimes' Low Dose, Big Benefits Campaign. In addition, Philips and March of Dimes will collaborate to identify key research areas, leveraging aggregated app data and surveys to gather valuable insights that will help both organizations further educate and support the needs of mothers and babies.
'Our partnership with Philips reflects our shared commitment to ensuring families have access to trusted, timely information throughout pregnancy,' said Kelly Ernst, Senior Vice President and Chief Impact Officer at March of Dimes. 'Whether it's through our Mom and Baby Mobile Health Centers® or expanding digital health literacy via the Pregnancy+ app, we're meeting families where they are. Initiatives like this represent a meaningful step forward in our mission to improve health outcomes for all moms and babies—and it's partnerships like this that make that progress possible.'
Pregnancy+, the world's #1 pregnancy app with more than 80 million lifetime downloads, provides information and guidance throughout a pregnancy including over 800 articles, lifelike 3D baby models, a weekly pregnancy tracker, and audio/video courses led by health and well-being experts. Philips will create awareness campaigns highlighting the new March of Dimes content, including relevant links and assets, that will have broad reach across the United States through the Pregnancy+ app.
'As we continue to seek solutions to address maternal health challenges, initiatives like this can contribute to meaningful change,' said Brenda Kapner, Regional Business Unit Leader, Mother & Childcare, Philips North America. 'By combining our expertise and resources with those of March of Dimes, we aim to deliver accessible education and insights, while utilizing advanced data analysis to better understand and meet the needs of mothers and babies. Together, we have the opportunity to significantly impact maternal and child health outcomes.'
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, education, and advocacy, and provide programs and services so that every family can get the best possible start. Since 1938, we've built a successful legacy to support every pregnant person and every family. Visit marchofdimes.org or nacersano.org for more information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Redwire Launches New Venture Company, SpaceMD, to Commercialize Pharmaceutical Development in Space; Signs Trailblazing Royalty Agreement with ExesaLibero Pharma
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals. SpaceMD will take advantage of the unique microgravity environment in space through the use of Redwire's innovative and flight-proven Pharmaceutical In-Space Laboratory (PIL-BOX) technology to grow the seed crystals. 28 PIL-BOX systems have already flown in space and have successfully crystalized 17 compounds on the ISS, including insulin and other critical molecules. SpaceMD will sell or license these seed crystals to companies that can use them to create reformulated versions of existing drugs or entirely new therapeutics. As part of this launch, SpaceMD announced a trailblazing licensing agreement with ExesaLibero Pharma, Inc., an innovative pharmaceutical company developing new small molecule drugs to treat bone disease. Under the terms of the agreement, ExesaLibero Pharma will work with SpaceMD to advance and enhance its groundbreaking small-molecule drug ELP-004 and other relevant compounds via the PIL-BOX system. This drug could hold the key to controlling the insidious bone erosion that numerous debilitating diseases cause, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis. The results of these microgravity investigations will inform ExesaLibero Pharma's Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, ExesaLibero Pharma expects to initiate clinical trials that will lead to full approval of the drug for clinical use. Through this first-of-its-kind agreement, SpaceMD will receive royalties from any commercial sales of resulting pharmaceutical products. 'Redwire is excited to announce the formation of SpaceMD. This new entity represents the evolution of our PIL-BOXstrategy, moving from experimentation to full commercialization with significant upstream revenue potential,' said Peter Cannito, Chairman and CEO of Redwire. 'This agreement with ExesaLibero Pharma signals a revolutionary paradigm shift for commercial utilization of microgravity. Redwire and now SpaceMD are translating the benefits of microgravity research into product value for pharmaceutical companies with the goal of transforming the future of therapeutics and creating value for our stakeholders.' 'We have seen firsthand how the microgravity environment can be a game-changer for drug development, and we look forward to expanding our work with SpaceMD through this exciting collaboration,' said John Barnett, Ph.D., President and Chief Scientific Officer at ExesaLibero. 'This collaboration will help us continue to advance our drug development and discovery process and lead to better outcomes for patients and future astronauts.' Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. Redwire currently has eleven research and manufacturing facilities on the ISS, more than any other company in the world. Redwire's microgravity technology enables space biotechnology and pharmaceutical development, helping customers reach a commercial market and paving the way for microgravity research on future commercial space stations. Previous investigations conducted by Redwire have been with partners such as Bristol Myers Squibb, Eli Lilly and Company, and Butler University. These efforts focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes. About Redwire Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Redwire's approximately 1,300 employees located throughout the United States and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit About SpaceMD SpaceMD is a subsidiary of Redwire Corporation focused on leveraging the microgravity environment of space to create new advances in pharmaceuticals, biotech, and other fields. SpaceMD utilizes innovative, flight-proven Redwire hardware to conduct this potentially life-enhancing work. SpaceMD uses the unique nature of space to benefit life on Earth.
Yahoo
7 hours ago
- Yahoo
Hims & Hers Q2 2025: What You Need to Know Ahead of Earnings
Hims & Hers Health (NYSE:HIMS) reports Q2 2025 earnings after U.S. markets close on Monday, August 4. Analysts expect revenue of around $552 million, up 75% YoY, and adjusted EPS near $0.15, roughly up 15% YoY. Despite the volatility, shares are up 154% YTD, pushing the forward P/E to roughly 57. Subscriber growth remains the core engine investors care about. Subscribers increased 38% in Q1, reaching 2.4 million. Weight-loss GLP-1 offerings are a swing factor, but Novo Nordisk (NYSE:NVO) ended its partnership on 23 Jun 2025, citing illegal mass compounding and deceptive marketing, which sent Hims down 30%. Analysts estimate that up to half of Hims' projected weight-loss revenue could be at risk. Investors need clarity on FDA scrutiny, formulary access, and whether compounded semaglutide margins can hold. Marketing spend, revenue per average user, and progress on the ZAVA integration will also be closely watched. Management guides FY25 revenue of $2.32.4 billion and low-teens EBITDA margins. Any uplift to those guides or clean regulatory commentary could keep momentum intact. But with valuation stretched, even a top-line beat may disappoint if churn ticks up or compliance costs bite. Q2 will test whether the telehealth disrupter can scale responsibly before regulators step in. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Wire
7 hours ago
- Business Wire
Guardian Pharmacy Services Strengthens Pacific Northwest Presence with Acquisition of Oregon-based Managed Healthcare Pharmacy
ATLANTA--(BUSINESS WIRE)-- Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care (LTC) pharmacy services companies, today announced its acquisition of Managed Healthcare Pharmacy, a leading LTC pharmacy in Oregon with locations in Eugene and Medford. This transaction marks a significant milestone for Guardian, establishing its first physical footprint in the state and expanding its presence in the Pacific Northwest. The newly acquired pharmacy serves residents in assisted living and behavioral health communities, as well as individuals with intellectual and developmental disabilities. "This acquisition allows us to expand our presence in the Pacific Northwest with a team already known for exceptional care and trusted partnerships,' said Fred Burke, president and CEO of Guardian Pharmacy Services. Established in 1991, Managed Healthcare Pharmacy is one of Oregon's largest LTC pharmacies, with a strong track record of service in LTC communities across the state and into Washington. All existing leadership and staff will remain in place, and the pharmacy will continue operating under its existing name. 'We continue to grow in regions where senior living operators value more dependable, high-touch support from established LTC pharmacies,' said Fred Burke, president and CEO of Guardian Pharmacy Services. 'Managed Healthcare Pharmacy has built a strong reputation in Oregon and Washington for its clinical expertise and deep commitment to the communities it serves. This acquisition allows us to expand our presence in the Pacific Northwest with a team already known for exceptional care and trusted partnerships.' As with Guardian's other acquisitions, Managed Healthcare Pharmacy will benefit from the company's locally operated business model, supported by its centralized corporate team. This enables the local pharmacy to remain focused on exceptional customer service and the specialized needs of the communities and residents they serve, while Guardian assists with the many complex behind-the-scenes business functions, including data analytics, HR, IT, payor relations, national sales and more. About Guardian Pharmacy Services Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities ('LTCFs') to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of more than 50 pharmacies nationwide, Guardian is dedicated to providing exceptional service to over 189,000 residents and approximately 7,000 LTCFs across 38 states (as of March 31, 2025). Forward-Looking Statements This press release contains forward-looking statements, including statements regarding our anticipated growth and expectations related to synergies and integration of the acquired pharmacy's operations and employees. These statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, including those described in Guardian's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission from time to time, and which are publicly available at and via our website, Actual results may differ materially from those expressed or implied in these statements. Guardian undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
